Yahoo Finance Keppel Full Year 2023 Earnings: EPS Misses Expectations
Keppel (SGX:BN4) Full Year 2023 Results
Key Financial Results
Revenue: S$6.97b (up 5.2% from FY 2022).
Net income: S$885.4m (up 5.0% from FY 2022).
Profit margin: 13% (in line with FY 2022).
EPS: S$0.50 (up from S$0.47 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Keppel EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 4.1%.
The primary driver behind last 12 months revenue was the Infrastructure segment contributing a total revenue of S$4.97b (71% of total revenue). Notably, cost of sales worth S$5.01b amounted to 72% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to S$728.3m (65% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of S$44.1m. Explore how BN4's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Industrials industry in Asia.
Performance of the market in Singapore.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Before we wrap up, we've discovered 3 warning signs for Keppel (1 doesn't sit too well with us!) that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
